MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health DSO Ratio 2011-2026 | OPK
Annual DSO Ratio OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 240 | 252 | 70.3 | 56.1 | 53.5 | 63.8 | 59.7 | 64 | 74.5 | 155 | 92.3 | 119 | 183 | 164 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 252 | 53.5 | 118 |
Quarterly DSO Ratio OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.9 | 61.7 | 55.7 | 54.3 | 60.1 | 83.9 | 57.1 | 47.8 | - | 31.3 | 31.3 | 65.5 | 58.5 | 61.6 | 60.5 | 50.8 | 52.8 | 61 | 86.7 | 90.8 | 54.8 | 53.7 | 54.3 | 57.1 | 59.2 | 52.6 | 49.8 | 55.4 | 93.8 | 61.4 | 51.6 | 66.1 | 81.4 | 67.4 | 56.3 | 64.9 | 64 | 124 | 417 | 324 | 71.4 | 92.2 | 77.4 | 81.4 | 87.2 | 87.4 | 75.7 | 59.5 | 119 | 164 | 189 | 175 | 198 | 168 | 136 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 417 | 31.3 | 89.2 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
82.1 | $ 9.19 | 2.06 % | $ 612 M |  USA |
|
Biodesix
BDSX
|
41.7 | $ 15.31 | 4.22 % | $ 1.99 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 74.11 | -2.15 % | $ 5 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
101 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 463.46 | 1.43 % | $ 13.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 159.84 | 1.16 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 165.65 | -0.81 % | $ 28.5 B | USA |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.67 | 0.11 % | $ 432 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.26 | -1.46 % | $ 386 M | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.22 | -16.44 % | $ 6.64 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 261.71 | 1.72 % | $ 26 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
53.1 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 125.17 | 1.11 % | $ 19.9 B | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
28.1 | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 7.67 | 0.72 % | $ 454 M | USA |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 266.56 | 0.81 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
34.5 | $ 59.22 | -4.09 % | $ 4.45 B | USA |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 7.87 | -2.82 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
81.5 | $ 193.75 | -3.17 % | $ 19.1 B | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.63 | 0.08 % | $ 277 M | USA |
 |
Sotera Health Company
SHC
|
43.9 | $ 13.82 | -0.43 % | $ 3.92 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.65 | 0.51 % | $ 941 M | USA |
 |
Soleno Therapeutics
SLNO
|
27 | $ 30.84 | -2.77 % | $ 1.57 B | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 25.23 | -2.02 % | $ 701 M | USA |
 |
DarioHealth Corp.
DRIO
|
56.7 | $ 8.05 | 7.27 % | $ 32.1 M | Israel |
 |
DexCom
DXCM
|
87 | $ 66.28 | 0.51 % | $ 25.9 B | USA |
 |
Neuronetics
STIM
|
48.7 | $ 1.47 | -8.12 % | $ 96.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | $ 104.91 | - | $ 19.8 B | USA |